EGFR mutations and abnormal trafficking in cancers.

Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor and a member of the ErbB receptor family. As a significant cancer driver, EGFR undergoes mutations such as gene amplification or overexpression in a wide range of malignant tumors and is closely associated with tumorigenesis. This review examines the aberrant expression of EGFR in several common cancers and summarizes the current therapeutic strategies developed for this receptor. Additionally, this review compares the differences in EGFR activation, internalization, endocytosis, and sorting in normal and cancer cells, and highlights some regulatory factors that influence its trafficking process.Kindly check and confirm the edit made in the title.Yes, correctAs per journal instructions structured abstract is mandatory kindly provideThe abstract format does not apply to Review articles. © 2024. The Author(s), under exclusive licence to Springer Nature B.V.

Citation

Xiang Kang, Rendong Li, Xiaolei Li, Xinping Xu. EGFR mutations and abnormal trafficking in cancers. Molecular biology reports. 2024 Aug 21;51(1):924

Mesh Tags

Substances

PMID: 39167290

search → result